Who's the biggest HIV drug seller of all?

Who's the Big Kahuna of HIV drugs? If you said GlaxoSmithKline (NYSE: GSK) or Abbott Laboratories (NYSE: ABT), you're wrong. It's Gilead Sciences (NASDAQ: GILD), at least according to sales figures compiled by Reuters.

Gilead drugs occupy the top two slots in a global ranking of HIV meds by sales. Truvada sits on top with $2.49 billion in 2009 sales; Atripla (a Gilead/Bristol-Myers Squibb med) is second with $2.38 billion; and Viread is in seventh place with $668 million. Add it up and you'll get more than $5.5 billion.

Even the big GlaxoSmithKline-Pfizer partnership, ViiV, doesn't come close to that. The venture's Epzicom came in at fifth place with $855 million, while Combivir nabbed eighth place with $665 million and Epivir came in 10th with $542 million. Of course, GSK and Pfizer are hoping that their combination pipeline will eventually boost ViiV drugs up in the rankings.

Merck, Bristol-Myers, Abbott Laboratories and Johnson & Johnson all have drugs in the top 10.

- read the Reuters ranking

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.